In a new report titled: The productivity agenda – moving beyond cost reduction in financial services, PwC sets out the important challenges and opportunities facing the financial services industry and the ways in which senior executives should respond if they wish to move beyond simple cost cutting and improve profitability in the long term. With banks struggling to improve … [Read more...] about Traditional cost-cutting measures aren’t enough to solve current profitability crisis in Financial Services industry
Briefing
NRF Says ‘State of the Economy is Sound’ and Forecasts Retail Sales Will Grow Between 3.8 and 4.4 Percent
The National Retail Federation today forecast that retail sales during 2019 will increase between 3.8 percent and 4.4 percent to more than $3.8 trillion despite threats from an ongoing trade war, the volatile stock market and the effects of the government shutdown. “We believe the underlying state of the economy is sound,” NRF President and CEO Matthew Shay said. “More … [Read more...] about NRF Says ‘State of the Economy is Sound’ and Forecasts Retail Sales Will Grow Between 3.8 and 4.4 Percent
Media Release: Cyber Threat Analysis Tools at CyberTech 2019
Cyber Threat Analysis Tools at CyberTech 2019 … [Read more...] about Media Release: Cyber Threat Analysis Tools at CyberTech 2019
Getting the most out of your data
Learn how to use AI and Machine Learning to gain new understanding using existing data within your organization. Analytics workshop at Microsoft Ignite … [Read more...] about Getting the most out of your data
The number of product approvals for cell and gene therapies will grow in the coming years
Statement from FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies The FDA is witnessing a surge of cell and gene therapy products entering early development, evidenced by a large upswing in the number of … [Read more...] about The number of product approvals for cell and gene therapies will grow in the coming years